Processa Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Processa Pharmaceuticals, Inc. (PCSA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-18
- Processa Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $1.40M, a 39.13% decline from fiscal 2024.
- Processa Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.30M, a 25.81% decline from fiscal 2023.
- Processa Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $3.10M, a 58.11% decline from fiscal 2022.
- Processa Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $7.40M, a 155.17% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $1.40M 10-K · filed 2026-03-18 |
| 2024-12-31 | $2.30M 10-K · filed 2026-03-18 |
| 2023-12-31 | $3.10M 10-K · filed 2025-03-20 |
| 2022-12-31 | $7.40M 10-K · filed 2024-03-29 |
| 2021-12-31 | $2.90M 10-K · filed 2023-03-30 |
| 2016-12-31 | $148.18K 10-K · filed 2017-09-25 |
| 2015-12-31 | $1.36M 10-K · filed 2017-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |